Literature DB >> 34546483

The cancer-related transcription factor Runx2 combined with osteopontin: a novel prognostic biomarker in resected osteosarcoma.

Shoulei Liang1, Yong Li1, Baocang Wang2.   

Abstract

PURPOSE: Osteosarcoma is the most common primary bone cancer in children and young adults. Recent experimental evidence has indicated that Runx2/OPN axis play important roles in the metastasis of osteosarcoma cells. The present study aimed to explore their relationship and prognostic significance in surgically resected osteosarcoma.
METHODS: The expression of runt-related transcription factor2(Runx2) and osteopontin (OPN) in clinical specimens from 105 osteosarcoma patients were detected by immunohistochemistry. The correlations between Runx2, OPN, and clinicopathologic data were analyzed by Chi-square (χ2) tests. The prognostic values were determined by univariate and multivariate survival analysis. The accuracy of oncologic outcome prediction was evaluated by receiver-operating characteristics curves.
RESULTS: The results showed there is a significant positive correlation between Runx2 and OPN expression at protein levels (P = 0.015). Runx2 and OPN were both independent predictors for overall survival and metastasis-free survival. When Runx2 and OPN were taken into consideration together, the predictive range was extended and the sensitivity was improved, and more significant and better biomarkers for osteosarcoma metastasis and survival.
CONCLUSIONS: These results suggest that a combined Runx2/OPN expression could be a valuable independent predictor of tumor metastasis and survival in osteosarcoma patients.
© 2021. Japan Society of Clinical Oncology.

Entities:  

Keywords:  OPN; Osteosarcoma; Prognosis; Runx2

Mesh:

Substances:

Year:  2021        PMID: 34546483     DOI: 10.1007/s10147-021-02025-4

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  23 in total

1.  Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation.

Authors:  P Ducy; R Zhang; V Geoffroy; A L Ridall; G Karsenty
Journal:  Cell       Date:  1997-05-30       Impact factor: 41.582

2.  Runt-related transcription factor 2 in human colon carcinoma: a potent prognostic factor associated with estrogen receptor.

Authors:  Tomohiko Sase; Takashi Suzuki; Koh Miura; Kenichi Shiiba; Ikuro Sato; Yasuhiro Nakamura; Kiyoshi Takagi; Yoshiaki Onodera; Yasuhiro Miki; Mika Watanabe; Kazuyuki Ishida; Shinobu Ohnuma; Hiroyuki Sasaki; Ryuichiro Sato; Hideaki Karasawa; Chikashi Shibata; Michiaki Unno; Iwao Sasaki; Hironobu Sasano
Journal:  Int J Cancer       Date:  2012-04-17       Impact factor: 7.396

3.  The cancer-related transcription factor RUNX2 modulates expression and secretion of the matricellular protein osteopontin in osteosarcoma cells to promote adhesion to endothelial pulmonary cells and lung metastasis.

Authors:  Francisco Villanueva; Hector Araya; Pedro Briceño; Nelson Varela; Andres Stevenson; Sofia Jerez; Fabian Tempio; Jonas Chnaiderman; Carola Perez; Milena Villarroel; Emma Concha; Farzaneh Khani; Roman Thaler; Flavio Salazar-Onfray; Gary S Stein; Andre J van Wijnen; Mario Galindo
Journal:  J Cell Physiol       Date:  2019-01-13       Impact factor: 6.384

4.  Ets-1 and runx2 regulate transcription of a metastatic gene, osteopontin, in murine colorectal cancer cells.

Authors:  Philip Y Wai; Zhiyong Mi; Chengjiang Gao; Hongtao Guo; Carlos Marroquin; Paul C Kuo
Journal:  J Biol Chem       Date:  2006-05-01       Impact factor: 5.157

Review 5.  Current treatment of osteosarcoma.

Authors:  W S Ferguson; A M Goorin
Journal:  Cancer Invest       Date:  2001       Impact factor: 2.176

6.  Runx2 in human breast carcinoma: its potential roles in cancer progression.

Authors:  Yoshiaki Onodera; Yasuhiro Miki; Takashi Suzuki; Kiyoshi Takagi; Jun-ichi Akahira; Takuya Sakyu; Mika Watanabe; Satoshi Inoue; Takanori Ishida; Noriaki Ohuchi; Hironobu Sasano
Journal:  Cancer Sci       Date:  2010-10-12       Impact factor: 6.716

Review 7.  Osteosarcoma.

Authors:  J Ritter; S S Bielack
Journal:  Ann Oncol       Date:  2010-10       Impact factor: 32.976

8.  RUNX2 (6p21.1) amplification in osteosarcoma.

Authors:  Sounak Gupta; Tatsuo Ito; Deepu Alex; Chad M Vanderbilt; Jason C Chang; Nasrin Islamdoust; Yanming Zhang; Khedoudja Nafa; John Healey; Marc Ladanyi; Meera R Hameed
Journal:  Hum Pathol       Date:  2019-10-25       Impact factor: 3.466

9.  New small molecules targeting apoptosis and cell viability in osteosarcoma.

Authors:  Doris Maugg; Ina Rothenaigner; Kenji Schorpp; Harish Kumar Potukuchi; Eberhard Korsching; Daniel Baumhoer; Kamyar Hadian; Jan Smida; Michaela Nathrath
Journal:  PLoS One       Date:  2015-06-03       Impact factor: 3.240

10.  Correlation of WWOX, RUNX2 and VEGFA protein expression in human osteosarcoma.

Authors:  Jilong Yang; Linru Zhao; Wei Tian; Zhichao Liao; Hong Zheng; Guowen Wang; Kexin Chen
Journal:  BMC Med Genomics       Date:  2013-12-15       Impact factor: 3.063

View more
  1 in total

1.  Hyaluronic Acid Correlates With Bone Metastasis and Predicts Poor Prognosis in Small-Cell Lung Cancer Patients.

Authors:  Cong Zhao; Zhiyun Zhang; Xingsheng Hu; Lina Zhang; Yanxia Liu; Ying Wang; Yi Guo; Tongmei Zhang; Weiying Li; Baolan Li
Journal:  Front Endocrinol (Lausanne)       Date:  2022-01-26       Impact factor: 5.555

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.